Regular biotech is already very cost-efficient, it's just a matter of putting the gene in, not breaking anything, and then optimising the hell out of the protoc

Regular biotech is already very cost-efficient, it's just a matter of putting the gene in, not breaking anything, and then optimising the hell out of the protocol (optimising temperature, pressure, nutrient mix etc. in your bioreactors). For synthetic biology, I have no idea why this is not commercially feasible. We probably oversimplify the cell's system too much, so that introducing a multi-level computer breaks things we don't know about? But I'm purely speculating.